Search

Your search keyword '"P. K. Jayachandran"' showing total 7 results
Start Over Author "P. K. Jayachandran"
7 results on '"P. K. Jayachandran"'

1. Outcomes of patients with hematologic malignancies and COVID-19 from the Hematologic Cancer Registry of India

Author

Arihant Jain, Lingaraj Nayak, Uday Prakash Kulkarni, Nikita Mehra, Uday Yanamandra, Smita Kayal, Sharat Damodar, Joseph M. John, Prashant Mehta, Suvir Singh, Pritesh Munot, Sushil Selvarajan, Venkatraman Radhakrishnan, Deepesh Lad, Rajan Kapoor, Biswajit Dubashi, Ram S. Bharath, Hasmukh Jain, P. K. Jayachandran, Jeyaseelan Lakshmanan, Thenmozhi Mani, Jayashree Thorat, Satyaranjan Das, Omprakash Karunamurthy, Biju George, Manju Sengar, and Pankaj Malhotra

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Published
2022
Full Text
View/download PDF

2. Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium

Author

Sengar, Manju, primary, Korula, Anu, additional, Ganesan, Prasanth, additional, Rajendra, Akhil, additional, Jain, Hasmukh, additional, Samuel, Prasanna, additional, P K, Jayachandran, additional, Prakash, Gaurav, additional, John, M. Joseph, additional, Palassery, Rasmi, additional, Nair, Chandran K., additional, Shet, Tanuja, additional, Selvarajan, Sushil, additional, Nayak, Lingaraj, additional, Karunakaran, Parathan, additional, NA, Fouzia, additional, Prakash, Om, additional, Bagal, Bhausaheb, additional, Mehra, Nikita, additional, Kumaran, Saranya, additional, Epari, Sridhar, additional, Thorat, Jayshree, additional, Radhakrishnan, Venkatraman, additional, and Abraham, Aby, additional

Published
2022
Full Text
View/download PDF

4. Effectiveness of End of Therapy PET Based Deauville Scoring in Predicting Outcomes in Hodgkin's Lymphoma: A Real-World Experience

Author

Mehra, Nikita, primary, Ganesan, Prasanth, additional, Radhakrishnan, Venkatraman, additional, Ganesan, Trivadi S, additional, Dhanushkodi, Manikandan, additional, Sundersingh, Shirley, additional, Shankar, S Krupa, additional, P K, Jayachandran, additional, Kannan, Krishnarathnam, additional, S M, Carthikeyan, additional, and Sagar, Tenali Gnana, additional

Published
2018
Full Text
View/download PDF

5. Patterns of Infection and Mortality Associated with Intensive AML Induction Therapy: 10 Year Experience from a Tertiary Cancer Centre in India

Author

Kumar, Hemanth, primary, Mehra, Nikita, additional, Ganesan, Prasanth, additional, Radhakrishnan, Venkatraman, additional, Dhanushkodi, Manikandan, additional, P K, Jayachandran, additional, Ganesan, Trivadi S, additional, Shankar, S Krupa, additional, Sagar, Tenali Gnana, additional, and Kannan, Krishnarathinam, additional

Published
2018
Full Text
View/download PDF

7. Clinicopathological characteristics, prognostic factors, and outcomes in peripheral T-cell lymphoma: Experience from a single center in India

Author

Siva Sree Kesana, Prasanth Ganesan, Tenali Gnana Sagar, Krishnarathinam Kannan, Trivadi S Ganesan, Manikandan Danushkodi, Nikita Mehra, P K Jayachandran, Archit Joshi, Arun Kumar, Gangothri Selvarajan, Shirley Sundersingh, and Venkatraman Radhakrishnan

Subjects
chemotherapy, india, low- and middle-income country, lymphoma, peripheral t-cell lymphomas, survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Background: Peripheral T-cell lymphomas (PTCL) are a heterogeneous group of diseases with aggressive behavior and inferior outcomes as compared to B-cell lymphomas. We report the outcomes from a single center over a period of 18 years. Methods: The baseline clinical features, pathological subtypes, and prognostic factors of all patients with PTCL treated at our center between January 2000 and December 2017 were retrospectively analyzed. Event-free survival (EFS) and overall survival (OS) were calculated using the Kaplan–Meier method and prognostic factors were compared using the log-rank test. Results: During the study period, 144 patients (2–74 years) were diagnosed with PTCL. Male patients were 101 (70%) and females were 43 (30%). Mean age at diagnosis was 43.5 years (20–74 years) for adults (≥ ≥18 years). Of the 144 patients, 42 (29%) had limited stage (Stage I/II) and 102 (71%) had advanced-stage disease (III/IV). The most common histological diagnosis was PTCL-not otherwise specified observed in 61 patients (42.4%) followed by anaplastic large-cell lymphoma (ALCL) in 65 patients (45.2%). The median duration of follow-up was 70.5 months (range, 1–218 months). Five-year OS and EFS for the entire population were 55% and 33%, respectively. Patients with limited stage had better survival when compared to those with advanced disease. Five-year EFS was 52% versus 25% (P = 0.006) and 5-year OS was 70% versus 47% (P = 0.02) in limited and advanced stage, respectively. Patients with PTCL, anaplastic lymphoma kinase (ALK)-positive ALCL and ALK-negative ALCL had 5-year EFS and OS of 20% and 38%, 46% and 76%, 43% and 76%, respectively (P value for EFS = 0.009 and OS < 0.001). Conclusion: Majority of patients with PTCL at our center presented with advanced-stage disease. Outcomes of patients with ALCL are better than those diagnosed with other subtypes of PTCL.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results